Inventaire - your friends and communities are your best library

Using modified antigenic sequences to develop cancer vaccines: are we losing the focus?

Published in: PLOS MEDICINE

Date of publication: November 2004

Language: English

Main subject: vaccine development

Bibliographic databases:

Cites articles 12

Date

Title

Authors

October 1, 1979

T-lymphocyte response to cytochrome c. I. Demonstration of a T-cell heteroclitic proliferative response and identification of a topographic antigenic determinant on pigeon cytochrome c whose immune recognition requires two complementing major histoc,T-lymphocyte response to cytochrome c. I. Demonstration of a T-cell heteroclitic proliferative response and identification of a topographic antigenic determinant on pigeon cytochrome c whose immune recognition requires two complementing major histocompatibility complex-linked immune response genes
September 1, 1985

Cytotoxic T cells recognize fragments of the influenza nucleoprotein
December 13, 1991

A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma,A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma
September 1, 1996

Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues
October 1, 1996

Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides
February 1, 1998

Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues

,
June 1, 1999

Modification of cysteine residues in vitro and in vivo affects the immunogenicity and antigenicity of major histocompatibility complex class I-restricted viral determinants
June 1, 2000

Cancer-induced defective cytotoxic T lymphocyte effector function: another mechanism how antigenic tumors escape immune-mediated killing
January 1, 2001

Cancer vaccines based on dendritic cells loaded with tumor-associated antigens
December 1, 2002

Multiepitope CD8(+) T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting

, ,
November 2004

Diversity and recognition efficiency of T cell responses to cancer

,
August 1, 2004

Poor immunogenicity of a self/tumor antigen derives from peptide-MHC-I instability and is independent of tolerance

,

Article -

Welcome to inventaire

The library of your friends and communities

You are offline